Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

Hematological Oncology - United Kingdom
doi 10.1002/hon.51_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Second Generation BTK Inhibitors Impair the Anti-Fungal Response of Macrophages and Neutrophils From CLL Patients

American Journal of Hematology
Hematology
2020English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Cell Line‐based Assessment of BTK Inhibitors

British Journal of Pharmacology
Pharmacology
2020English

Is Cancer Incidence Modified by SGLT2 Inhibitors?

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

Second Cancer Incidence and Cancer Mortality Among Chronic Lymphocytic Leukaemia Patients: A Population-Based Study

British Journal of Cancer
Cancer ResearchOncology
2011English

Cardiac Dysfunction in Cancer Patients Receiving Chemotherapy

Journal of Evolution of Medical and Dental Sciences
2015English

Incidence of Chemotherapy-Induced Neutropenia in HIV-infected and Uninfected Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

South African Medical Journal
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy